| --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | On Today's Earnings Call | --- | --- | --- | --- | |--------------------------------------------|--------------------|-------------------------------------|--------------------------------------------------------------------| | | | | | | | | | | | Brett Monia, Ph.D. Chief Executive Officer | | Beth Hougen Chief Financial Officer | Richard Geary, Ph.D. Executive Vice President, De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant's telephone number, including area code ...

IONIS" FY 2020 Financial Results and Business Update February 24, 2021 On Today's Earnings Call | --- | --- | --- | --- | |--------------------------------------------|--------------------|-------------------------------------|--------------------------------------------------------------------| | | | | | | | | | | | Brett Monia, Ph.D. Chief Executive Officer | | Beth Hougen Chief Financial Officer | Richard Geary, Ph.D. Executive Vice President, Development | | | Eric Swayze, Ph.D. | Executive Vice Preside ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2020 Earnings Conference Call February 24, 2020 9:00 AM ET Company Participants Wade Walke - VP, IR Brett Monia - CEO Beth Hougen - CFO Richard Geary - EVP of Development Onaiza Cadoret - Chief Corporate Development and Commercial Officer Eric Swayze - EVP of Research Conference Call Participants Yaron Werber - Cowen Alex Thompson - Stifel Jim Birchenough - Wells Fargo Tyler Van Buren - Piper Sandler Vincent Chen - Bernstein Joel Beatty - Citi Yale Jen - Laidlaw ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other ...

IONIS" Investor Day 2020 December 7, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), TEGSEDI® (inotersen), WAYLIVRA® (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' wholly owned subsidiary. Any statement describing Ionis' goals, expectations, financial or other projection ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2020 Earnings Conference Call November 4, 2020 11:30 AM ET Company Participants Wade Walke – Vice President of Investor Relations Brett Monia – Chief Executive Officer Beth Hougen – Chief Financial Officer Onaiza Cadoret – Chief Corporate Development and Commercial Officer Richard Geary – Executive Vice President of Development Eric Swayze – Executive Vice President of Research Kyle Jenne – Chief Commercial Officer-Akcea Conference Call Participants Do Kim – BMO ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2020 OR Delaware 33-0336973 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 000-19125 Ionis Pharmaceuticals, Inc. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of Registrant as specified in its charter) For the Quarterly Period Ended June 30, 2020 Delaware 33-0336973 OR (State or othe ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2020 Earnings Conference Call August 5, 2020 11:30 AM ET Company Participants Wade Walke - Vice President of Investor Relations Brett Monia - Chief Executive Officer Beth Hougen - Chief Financial Officer Richard Geary - Executive Vice President of Development Onaiza Cadoret - Chief Corporate Development & Commercial Officer Conference Call Participants Jim Birchenough - Wells Fargo Ellie Merle - Cantor Fitzgerald Chad Messer - Needham & Company Tyler Van Buren - ...